DK1759702T3 - Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning - Google Patents

Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning

Info

Publication number
DK1759702T3
DK1759702T3 DK04748557T DK04748557T DK1759702T3 DK 1759702 T3 DK1759702 T3 DK 1759702T3 DK 04748557 T DK04748557 T DK 04748557T DK 04748557 T DK04748557 T DK 04748557T DK 1759702 T3 DK1759702 T3 DK 1759702T3
Authority
DK
Denmark
Prior art keywords
solution
preparing
prepared
latanoprost eye
latanoprost
Prior art date
Application number
DK04748557T
Other languages
Danish (da)
English (en)
Inventor
Bayardo Arturo Jimenez
Monta O Jose Ruben Tornero
Sanchez Marya Isabel Lopez
Olmos Enrique Cruz
Original Assignee
Bayardo Arturo Jimenez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35450648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1759702(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayardo Arturo Jimenez filed Critical Bayardo Arturo Jimenez
Application granted granted Critical
Publication of DK1759702T3 publication Critical patent/DK1759702T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04748557T 2004-05-26 2004-05-26 Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning DK1759702T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000034 WO2005115401A1 (es) 2004-05-26 2004-05-26 Un método para preparar una solución oftálmica de latanoprost y solución resultante

Publications (1)

Publication Number Publication Date
DK1759702T3 true DK1759702T3 (da) 2009-04-20

Family

ID=35450648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04748557T DK1759702T3 (da) 2004-05-26 2004-05-26 Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning

Country Status (12)

Country Link
US (4) US8293789B2 (sl)
EP (1) EP1759702B1 (sl)
AR (1) AR049113A1 (sl)
AT (1) ATE419854T1 (sl)
BR (1) BRPI0418866A (sl)
DE (1) DE602004018990D1 (sl)
DK (1) DK1759702T3 (sl)
ES (1) ES2320770T3 (sl)
PL (1) PL1759702T3 (sl)
PT (1) PT1759702E (sl)
SI (1) SI1759702T1 (sl)
WO (1) WO2005115401A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
EP2167546A1 (en) * 2007-07-11 2010-03-31 Ophthalmopharma AG Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
WO2009048929A1 (en) * 2007-10-08 2009-04-16 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US9481856B2 (en) 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
WO2010053487A1 (en) * 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
CN102458370A (zh) * 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
AU2020217732A1 (en) * 2019-02-06 2021-09-30 TearClear Corp. Systems and methods for preservative removal from ophthalmic formulations comprising complexing agents
US20220288090A1 (en) 2019-08-07 2022-09-15 Aneira Pharma Inc. Methods And Compositions For The Treatment Of Hair Loss
EP4167960A1 (en) * 2020-06-21 2023-04-26 i.com Medical GmbH Hyaluronic acid-based formulations for treatment and prevention of ocular hypertension and glaucoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP5011548B2 (ja) 1998-12-25 2012-08-29 株式会社アールテック・ウエノ 高眼圧症あるいは緑内障の処置用医薬組成物
AU3328601A (en) * 2000-02-01 2001-08-14 Cayman Chemical Co Inc Internal 1,15-lactones of fluprostenol and related prostaglandin F<sub>2alpha</sub> analogs and their use in the treatment of glaucoma and intraocular hypertension
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
AR035541A1 (es) 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio

Also Published As

Publication number Publication date
US20080021101A1 (en) 2008-01-24
BRPI0418866A (pt) 2007-11-20
PL1759702T3 (pl) 2009-06-30
EP1759702B1 (en) 2009-01-07
PT1759702E (pt) 2009-04-13
SI1759702T1 (sl) 2009-06-30
US20110098355A1 (en) 2011-04-28
ES2320770T3 (es) 2009-05-28
US20110105605A1 (en) 2011-05-05
WO2005115401A1 (es) 2005-12-08
US8293789B2 (en) 2012-10-23
EP1759702A1 (en) 2007-03-07
AR049113A1 (es) 2006-06-28
US20110098354A1 (en) 2011-04-28
DE602004018990D1 (de) 2009-02-26
ATE419854T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DK1759702T3 (da) Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
DK1898829T3 (da) Fremgangsmåde til fremstilling af en tandprotesedel og således fremstillet tandprotesedel
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK1896065T3 (da) Fremgangsmåde til fremstilling af vacciner
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1638750T3 (da) Fremgangsmåder til fremstilling af gelplader
DK1676786T3 (da) Fremgangsmåde til fremstilling af drikkevarer
DK3281939T3 (da) Kombination, der omfatter et stabilt krystal af 4-oxoquinolin sammensætning
DK1976868T3 (da) Edderkoppesilke-proteiner og fremgangsmåde til fremstilling af edderkoppesilke-proteiner
DK1629960T3 (da) Fremgangsmåde og forme til fremstilling af oftalmiske linser
FR2865631B1 (fr) Lunettes-masque
MY158073A (en) Process for producing optically active amine derivatives
DK2322511T3 (da) Fremgangsmåde til fremstilling af Telmisartan
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1864987T3 (da) Fremgangsmåder til fremstilling af 3-O-beskyttede morphinoner og 3-O-beskyttede morphinon-dienol-carboxylater
FI20030490A0 (fi) Menetelmä kuitukoostumuksen valmistamiseksi
DK1536685T3 (da) Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
DK1727782T3 (da) Fremgangsmåde til fremstilling af aminophenolforbindelser
DK1835816T3 (da) Fremgangsmåde til produktion af proteinhydrolysater
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1720852T3 (da) Fremgangsmåde til fremstilling af enantiomerrene 1-substituerede 3-aminoalkoholer
DK1784183T3 (da) Fremgangsmåder til fremstilling af isothiazolderivater
DK1794111T3 (da) Fremgangsmåde til fremstilling af cyclopentanon
DK2390326T3 (da) Fremgangsmåde til fremstilling af et humant type II-collagen